Journal of Cancer Research and Immuno-Oncology

OPEN ACCESS Freely available online

Commentary

Single-Cell Transcriptomic Profiling Advancing Precision Oncology and Cancer Immunotherapy

Marco Echeverría*

Department of Integrative Cancer Biology, Andean Institute of Biomedical Research, Quito, Ecuador

DESCRIPTION

Cancer is characterized by remarkable biological diversity that extends beyond differences among patients and includes extensive variation within individual malignant lesions. Cells occupying the same anatomical location often display distinct molecular characteristics, metabolic programs, proliferative capacities, and interactions with surrounding stromal populations. Conventional analytical techniques have provided valuable information regarding cancer biology; however, many of these methods evaluate mixed populations of cells, producing average molecular profiles that may conceal important cellular differences. During the past decade, single-cell transcriptomic profiling has transformed cancer research by enabling detailed examination of gene expression within individual cells. This technological development has significantly expanded understanding of cellular diversity, communication networks, disease progression, and therapeutic responsiveness. Within cancer research and immuno-oncology, single-cell transcriptomics has become an important approach for investigating the complex biological organization of malignant tissues and identifying cellular populations associated with clinical outcomes.

Every tissue contains numerous specialized cell types performing coordinated biological functions. Malignant lesions include cancer cells, fibroblasts, endothelial cells, pericytes, adipocytes, macrophages, dendritic cells, lymphocytes, plasma cells, and additional stromal populations interacting continuously through biochemical and mechanical signaling pathways. Earlier transcriptomic analyses frequently examined these mixed cellular environments as single biological samples. Although such investigations identified major molecular pathways involved in cancer progression, they could not determine which individual cell populations generated specific transcriptional signatures. Consequently, subtle yet biologically significant differences among neighboring cells often remained undetected.

One of the earliest observations arising from single-cell investigations was the remarkable heterogeneity among malignant cells occupying the same lesion. Although these cells frequently originate from a common ancestral clone, progressive biological adaptation results in considerable variation in transcriptional activity, metabolism, proliferation, migration, and stress responses. Some malignant cells display highly proliferative characteristics, whereas neighboring populations exhibit metabolic adaptation, cellular dormancy, or increased migratory potential. Such diversity contributes to variability in disease progression and therapeutic responsiveness observed within individual patients.

Endothelial cells responsible for blood vessel formation also demonstrate substantial molecular diversity when examined through single-cell transcriptomics. Different endothelial populations regulate vascular permeability, nutrient delivery, oxygen transport, and inflammatory cell trafficking according to local environmental conditions. Tumor-associated blood vessels often contain endothelial cells displaying transcriptional programs distinct from those observed in healthy tissues. These molecular differences contribute to irregular vascular architecture and influence regional variation in oxygen availability, metabolic activity, and therapeutic distribution.

Lymphocyte populations also exhibit remarkable transcriptional variability. Cytotoxic T lymphocytes, helper T cells, regulatory T cells, natural killer cells, B lymphocytes, and plasma cells each display multiple functional states associated with activation, differentiation, migration, metabolism, and cytokine production. Single-cell profiling enables investigators to distinguish subtle molecular differences among these populations while identifying specialized subgroups associated with favorable or unfavorable clinical outcomes. Such detailed characterization improves understanding of adaptive responses occurring throughout disease progression.

Dendritic cells have likewise benefited from single-cell investigation. These specialized antigen-presenting cells display considerable molecular diversity depending upon tissue location, developmental origin, and environmental exposure. Distinct dendritic cell populations differ in antigen processing, cytokine

Correspondence to: Marco Echeverría, Department of Integrative Cancer Biology, Andean Institute of Biomedical Research, Quito, Ecuador, E-mail : marco.echeverria@aibr-ecuador.edu

Received: 01-Jun-2026, Manuscript No. JCRIO-26-43986; **Editor assigned:** 03-Jun-2026, PreQC No. JCRIO-26-43986(PQ); **Reviewed:** 17-Jun-2026, QC No. JCRIO-26-43986; **Revised:** 24-Jun-2026, Manuscript No. JCRIO-26-43986 (R); **Published:** 01-Jul-2026, DOI: 10.35248/2684-1266.26.12.286

Citation: Echeverría M (2026). Single-Cell Transcriptomic Profiling Advancing Precision Oncology and Cancer Immunotherapy. J Cancer Res Immunooncol. 11:286.

Copyright: © 2026 Echeverría M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

secretion, migratory behavior, and communication with lymphocyte populations. Improved characterization of these cells contributes to greater understanding of mechanisms regulating adaptive responses during malignant disease.

Metabolic diversity has also become increasingly apparent through integration of transcriptomic and metabolomic analyses. Individual cellular populations display distinct expression of genes regulating glucose metabolism, amino acid utilization, lipid synthesis, mitochondrial activity, and oxidative stress responses. Such metabolic specialization reflects adaptation to regional differences in nutrient availability and oxygen concentration. Understanding these metabolic characteristics strengthens interpretation of biological variability within malignant tissues.

Liquid biopsy technologies complement tissue-based transcriptomic investigations by providing minimally invasive opportunities to monitor disease evolution over time. Circulating tumor cells, extracellular vesicles, cell-free nucleic acids, and soluble proteins obtained from peripheral blood provide additional information regarding molecular alterations occurring during treatment. Although liquid biopsy cannot fully replace direct tissue analysis, integration with single-cell transcriptomics strengthens longitudinal evaluation of biological changes associated with disease progression and therapeutic intervention.

Modern therapeutic development increasingly incorporates information obtained through single-cell technologies. Identification of rare cellular populations associated with resistance, recurrence, or metastatic dissemination provides opportunities to refine therapeutic strategies and improve patient selection. Molecular characterization of individual cellular subsets may also contribute to discovery of novel biomarkers supporting prediction of therapeutic responsiveness across different malignancies.

The microbiome has recently emerged as another factor influencing transcriptional diversity observed within malignant tissues. Microbial metabolites circulating throughout the body modify gene expression among epithelial cells, fibroblasts, endothelial cells, macrophages, and lymphocytes. Integration of microbiome research with single-cell transcriptomics has therefore become an active area of investigation seeking to clarify interactions between microbial ecology and host cellular biology.

CONCLUSION

Future progress in cancer research and immuno-oncology will increasingly depend upon technologies capable of resolving cellular diversity with exceptional precision. Single-cell transcriptomic profiling has fundamentally changed current understanding of malignant disease by revealing extensive molecular heterogeneity among cancer cells, stromal populations, vascular structures, and inflammatory cells. Continued integration of transcriptomics with spatial analysis, metabolomics, proteomics, computational biology, and clinical investigation will further strengthen knowledge regarding cellular communication and disease evolution. These multidisciplinary approaches are expected to improve biomarker discovery, enhance patient stratification, refine therapeutic development, and support increasingly individualized management strategies for a wide spectrum of human malignancies..